Skip to Main Content
Skip Nav Destination
Girl vaccine

Immunization schedule updated for 2022

February 17, 2022
Sean T. O’Leary, M.D., M.P.H., FAAP

Dr. O’Leary is vice chair of the AAP Committee on Infectious Diseases.

The 2022 Recommended Child and Adolescent Immunization Schedule released today reflects current guidance for vaccines and has been approved by the Academy, the Centers for Disease Control and Prevention and five other medical associations.

Similar to recent years, the cover page includes a table with an alphabetical listing of vaccines, approved abbreviations for each vaccine and vaccine trade names. Dengue vaccine (Dengvaxia) has been added to the table.

The notes are in alphabetical order. The following changes have been made to the notes:

  • Additional Information: The section on COVID-19 vaccination recommendations has been updated.
  • Dengue vaccination: A section has been added regarding routine recommendation for use of the vaccine.
  • Haemophilus influenzae type b (Hib) vaccination: Text has been edited to include recommendations for use of Vaxelis for routine and catch-up vaccination.
  • Hepatitis A vaccination: The note was updated to clarify the age for routine vaccination.
  • Human papillomavirus vaccination (HPV):
    • The note was updated to clarify when an HPV series is complete and no additional dose of HPV is recommended.
  • The special situations section was updated to clarify that people with immunocompromising conditions (including HIV infection) should receive three doses of HPV vaccine regardless of age at initial vaccination.
  • Measles, mumps and rubella (MMR) vaccination: The section on routine vaccination was updated to include the recommendations for the use of the combination measles, mumps, rubella and varicella (MMRV) vaccine.
  • Meningococcal serogroup A, C, W and Y vaccines (MenACWY):
  • Text has been added to clarify MenACWY vaccines can be administered simultaneously with serogroup B meningococcal (MenB) vaccines if indicated but at different anatomical sites, if feasible.
  • In the special situations section, the language for the dosing schedule for Menveo in infants was edited for clarity.

Other notable changes include the following:

Table 1 (Recommended Child and Adolescent Immunization Schedule for ages 18 or younger):

  • The text “School entry and adolescent vaccine age groups are shaded in gray” has been removed from the introductory sentences.
  • The colors of the age columns 4-6 years, 11-12 years and 16 years have been changed so they are similar to the other columns.
  • HPV row: For the column representing 9-10 years, the color was changed from blue with an asterisk to checked yellow. The legend now reads “Recommended vaccination can begin in this age group.”
  • Tetanus, diphtheria, acellular pertussis (Tdap) row: The text “Tdap” in the 11-12 year column has been changed to “1 dose.”
  • A row was added for dengue vaccine

Table 2 (catch-up schedule for children ages 4 months through 18 years):

  • Hib row: The text for the minimum interval between dose 2 and dose 3 has been edited to include Vaxelis and remove Comvax.
  • A row was added for dengue vaccine.

Table 3 (Recommended Child and Adolescent Immunization Schedule by Medical Indication):

  • HIV infection: The descriptive text for the sub-column was edited and now reads “<15% or total CD4 cell count of <200/mm3.”
  • Legend: The text that defines the checked yellow box has been edited to include “or vaccine.” The text now reads “Vaccination is recommended, and additional doses may be necessary based on medical condition or vaccine. See Notes.”
  • A row was added for dengue vaccine.

Dr. O’Leary is vice chair of the AAP Committee on Infectious Diseases.



Close Modal

or Create an Account

Close Modal
Close Modal